IPP Bureau
Novartis showcases its attractive growth pipeline
By IPP Bureau - December 03, 2021
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
North America accounts for 50 % of generic pharma market
By IPP Bureau - December 03, 2021
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
Neuberg Diagnostics expands to North India
By IPP Bureau - December 03, 2021
Collectively, these 10 laboratories are capable of processing about 10,000 samples in a day and deliver results within the given turnaround time
Over one lakh SARS-CoV-2 genomes sequenced till November
By IPP Bureau - December 03, 2021
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
Aster Volunteers offer free diabetes screening in India and UAE
By IPP Bureau - December 03, 2021
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
Booster dose for those above 40
By IPP Bureau - December 03, 2021
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
Serum seeks DCGI approval for booster dose in India
By IPP Bureau - December 02, 2021
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
Molnupiravir, a step closer to approval in the fight against Covid-19
By IPP Bureau - December 02, 2021
The U.S. FDA advisory committee voted 13-10 in favour of the oral antiviral medicine
Sai Life Sciences receive Certificate of Inspection from Japan PMDA
By IPP Bureau - December 02, 2021
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
Premas Biotech and Oravax to test their vaccine candidate against Omicron
By IPP Bureau - December 02, 2021
Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
Amrutanjan Health Care opens first store in Chennai
By IPP Bureau - December 02, 2021
The offline store launch will complement the E-commerce website in building a rich consumer shopping experience
Sanofi to acquire Origimm Biotechnology to treat acne with vaccine
By IPP Bureau - December 02, 2021
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Lupin partners with TTP for soft-mist inhalation tech platform
By IPP Bureau - December 02, 2021
Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants
GSK's antibody drug sotrovimab works against Omicron mutations
By IPP Bureau - December 02, 2021
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
ZyCoV-D to be initially administered in seven states
By IPP Bureau - December 02, 2021
The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20
